Essential Thrombocythemia — Trials

Essential Thrombocythemia — Trials · CancerIndex

Clinical trials

Registered studies

93 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 24
Recruiting: 15
Ph III recruiting: 2
Growth YoY: —
Industry share: 25%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (6)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01387763	A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms(DALIAH)	completed	Phase 3	202	Thomas Stauffer LarsenOTHER	1	Apr 27, 2022	clinicaltrials
NCT02076815	Anagrelide Retard in Essential Thrombocythemia(TEAM-ET)	completed	Phase 3	106	AOP Orphan Pharmaceuticals AGINDUSTRY	5	Jul 29, 2015